Skip to content
DataLookout
Menu

NCT06742996

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 35 versions: 35 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 150 → 145 locations
    • Study description expanded, about 278 words
  2. Notable Eligibility criteria expanded, about 15 words
    • Trial sites reduced: 155 → 150 locations
    • Secondary endpoints: details revised at 2 of 10 entries
  3. Minor Study sites revised (155)v33
  4. Minor Site details revised at 2 of 155 sitesv32
  5. Minor Site details revised at 28 of 155 sitesv31
  6. Minor Trial sites expanded: 152 → 155 locationsv30
  7. Minor Study sites revised (152)v29
  8. Minor Study sites: 151 to 152v28
  9. Minor Study sites: 149 to 151v27
  10. Minor Study sites: 148 to 149v26
  11. Minor Study sites: 149 to 148v25
  12. Minor Study sites revised (149)v24
  13. Minor Study sites revised (149)v23
  14. Minor Study sites: 148 to 149v22
  15. Minor Site details revised at 1 of 148 sitesv21
  16. Notable Lead sponsor: BeiGene to BeOne Medicinesv20 Show 7 more changesShow less
    • Eligibility criteria expanded, about 39 words
    • Study sites: 141 to 148
    • Primary completion date: Mar 31, 2029 to Aug 31, 2028
    • Study completion date: Oct 30, 2032 to Mar 30, 2032
    • Secondary endpoints: details revised at 9 of 10 entries
    • Study description expanded, about 35 words
    • Study title expanded, about 1 word
  17. Minor Study sites: 138 to 141v19
  18. Minor Study sites: 133 to 138v18
  19. Minor Study sites: 148 to 133v17
  20. Minor Study sites revised (148)v16
  21. Minor Site details revised at 6 of 148 sitesv15
  22. Minor Site details revised at 21 of 148 sitesv14
  23. Minor Site details revised at 8 of 148 sitesv13
  24. Minor Study sites revised (148)v12
  25. Minor Study sites revised (148)v11
  26. Minor Study sites revised (148)v10
  27. Minor Site details revised at 5 of 148 sitesv9
  28. Minor Study sites: 146 to 148
    • Start date: Feb 25, 2025 to Mar 5, 2025
    v8
  29. Minor Study sites revised (146)v7
  30. Minor Study sites: 145 to 146v6
  31. Minor Study sites: 140 to 145v5
  32. Minor Study sites: 138 to 140v4
  33. Minor Study sites: 1 to 138v3
  34. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 28, 2025 to Feb 25, 2025
    v2
  35. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
Timeframe: Approximately 41 months

Secondary (10)

Overall Survival (OS)
PFS as assessed by investigator (INV)
Overall Response Rate (ORR) as assessed by BIRC and by INV
Duration of Response (DOR) as assessed by BIRC and by INV
Complete Response Rate (CRR) as assessed by BIRC and by INV
Show 5 moreShow less
Time to first response as assessed by BIRC and by INV
Time to initiation of new anticancer therapy
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Non-Hodgkin Lymphoma High Grade Module 29 (EORTC-QLQ-NHL-HG29)
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Number of participants with treatment-emergent adverse events (TEAEs)

Arms and interventions

Arm A: sonrotoclax plus zanubrutinibExperimental

Sonrotoclax and zanubrutinib will be administered in combination.

Arm B: placebo plus zanubrutinibPlacebo comparator

Placebo and zanubrutinib will be administered in combination.

Drugs: Sonrotoclax, Zanubrutinib, Placebo

Sites

145 sites in 17 countries

United States 41, China 19, Japan 18, Brazil 10, Germany 7, United Kingdom 7, South Korea 6, Australia 5, Italy 5, New Zealand 5, Poland 5, Argentina 4, France 4, Spain 4, Turkey (Türkiye) 3, Austria 1, Puerto Rico 1